7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A regulatory breakdown of vaginal estradiol compounding legality under FDA 503A and 503B frameworks, how compounded products differ from FDA-approved formulations, and current safety and labeling requirements.
A clinical review of FDA Adverse Event Reporting System (FAERS) data for vaginal estradiol, including signal detection, label updates, and real-world safety evidence from post-market surveillance.
Full FDA approval history for vaginal estradiol products including Estrace Cream, Vagifem, Estring, and Imvexxy. Label requirements, boxed warning context, and post-market safety data.
A comprehensive review of every FDA label change for vaginal estradiol products from 2020 through 2026, including boxed warning revisions, new safety data, and clinical implications for prescribers and patients.
A detailed look at the vaginal estradiol regulatory pipeline, current FDA-approved products, label requirements, post-market safety data, and emerging next-generation formulations in development.
How the FDA and EMA differ on vaginal estradiol approval, labeling, safety monitoring, and prescribing guidance for genitourinary syndrome of menopause.
A clinical review of vaginal estradiol's FDA approval history, patent disputes, generic competition, and evolving labeling requirements for vulvovaginal atrophy treatment.